Looking for:
. |
.
.
Prednisone effect on neutrophil count
Blood cells. In: Basic Histology. Junqueira LC, Caneiro J eds. New York, NY. Abramson N, Melton B. Leukocytosis: basic of clinical assessment. Am Fam Physician ; Prednisone-induced leukocytosis. Influenced of dosage, method and duration of administration on the degree of leukocytosis. Am J Med ; Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes.
Circulation ; Regulation of L-selectin and CD18 on bovine neutrophils by glucocorticoids: effects of cortisol and dexamethasone. J Leukoc Biol ; L-selectin expression on polymorphonuclear leukocytes and monocytes in premature infants: reduced expression after dexamethasone treatment for bronchopulmonary dysplasia. J Pediatr ; Mechanisms of glucocorticoid-induced down-regulation of neutrophil L-selectin in cattle: evidence for effects at the gene-expression level and primarily on blood neutrophils.
Glucocorticoids inhibit apoptosis of human neutrophils. Blood ; Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol ; Leukokinetic studies. A non-steady-state kinetic evaluation of the mechanism of cortisone-induced granulocytosis.
J Clin Invest ; Daily doses of prednisone up to 60 mg resulted in dose- and time-dependent effects on biomarkers of bone metabolism. OC and P1NP are biomarkers of bone formation. On Day 1, plasma OC significantly decreased relative to placebo as early as 2 h post-dose, and continued to decrease in a dose-dependent manner until 12 h post-dose Fig.
P1NP levels increased slightly relative to placebo on Day 2, and then decreased in a dose- and time-dependent manner until Day 8 Fig. Mean change from baseline difference from placebo in biomarkers of bone metabolism.
Urinary NTX is a biomarker of bone loss. The results for fasting glucose and insulin on Days 1 and 8 are shown in Table 4. Increases from baseline in both glucose and insulin concentrations at 0. After 6 days of prednisone treatment, the changes from baseline in both glucose and insulin concentrations relative to placebo were not significant at most time points data not shown.
The effect of prednisone relative to placebo on serum triglyceride levels was variable. On Day 1, prednisone 20 mg and 40 mg significantly raised triglyceride levels. On Day 8, prednisone raised triglyceride levels, but the relationship to dose was inconsistent, and the impact generally was not significant Table 4. Dose- and time-dependent effects of prednisone on adiponectin were also observed relative to placebo. On Day 8, adiponectin was significantly increased with higher prednisone doses Table 4.
However, no clear pattern for the treatment arms appeared in either assessment. There were no serious adverse events SAEs or deaths reported. There were no clinically significant changes in vital signs or body weight at any time point. The incidence of AEs with prednisone was not dose related.
Three subjects reported severe AEs; all were headaches experienced while on prednisone 2. This study was designed to characterize the dose—response and time course of prednisone effects on biomarkers of GC receptor agonism in a healthy adult population over 7 days. Daily doses of prednisone up to 60 mg were generally well-tolerated and resulted in dose- and time-dependent effects on a number of biomarkers. As would be expected, a decrease relative to placebo was noted in biomarkers of bone formation OC and P1NP , whereas there was an increase in a biomarker of bone turnover uNTX.
Also as expected, suppression of morning cortisol levels was seen at higher prednisone doses. Metabolic effects on glucose concentrations, OGTT, and triglyceride levels were modest and generally not statistically significant; however, adiponectin levels were significantly increased relative to placebo with higher prednisone doses by Day 8. GCs are reasonably safe for short-term use. However, serious complications have often been reported with long-term use [ 10 , 11 ].
In this study, inhibition of the HPA axis was evident by the potent, dose-dependent suppression of serum cortisol following the first dose of prednisone. As expected, with regard to the low-dose ACTH stimulation test, the subjects that took longer to return to normal were in the treatment groups that received the higher doses of prednisone in Period 3.
GCs are well known for their ability to affect circulating white blood cell profiles. It is generally acknowledged that administration of GC induces a transient fall in circulating lymphocytes, which is maximal 4—6 h after administration [ 19 ], particularly if the drug is administered in the morning [ 20 ]; this is thought to arise mainly from a reduced efflux of lymphocytes from lymphoid organs [ 13 ].
The transient fall is followed by a subsequent return to normal values within 12—24 h [ 19 ]. This was demonstrated in the present study, where all doses of prednisone reduced lymphocyte counts within 2 h, with maximum effect seen at 4—8 h. Levels started to return towards normal by 8 h after dosing, and were close to baseline values by 24 h. The increases in lymphocyte count on the mornings prior to dosing were likely due to a rebound phenomenon reported previously for GCs [ 21 ].
Conversely, the dose-dependent decreases in eosinophils observed in the first 24 h continued through Day 8, albeit at a diminishing rate. The increased neutrophil counts observed following GC treatment are consistent with the literature, and are thought to be due to increased release from bone marrow and decreased movement out of the blood into tissue sites [ 21 , 22 ].
Osteoporosis, a condition characterized mainly by a reduction in bone mineral density BMD , is a well-established side effect of chronic GC therapy.
In fact, chronic use of GCs increases the already increased risk of osteoporosis in patients with RA by twofold [ 23 , 24 ]. Some studies suggest that the associated fractures actually occur at higher BMD levels in patients treated with GCs than in patients not treated with GCs [ 25 ].
However, low-dose GC therapy has been recognized to avert the deleterious effects of GCs seen at higher doses, possibly due its anti-inflammatory effect countering the bone loss caused by chronic inflammation; a literature review on the safety of long-term, low-dose GC therapy in patients with rheumatic diseases demonstrated that AEs can in fact be quite modest [ 26 ].
For example, the data from four extensively reviewed randomized controlled trials showed that BMD loss over 2 years of low-dose prednisone treatment is not significantly different from that with placebo. On the other hand, osteoporosis is still likely to be the most common side effect of chronic low-dose GC therapy [ 27 ].
Many studies maintain the idea that reduced bone formation is predominantly responsible for the GC-associated bone loss [ 28 , 29 ]. OC, an osteoblast-derived protein involved in bone formation, is routinely utilized as a biomarker because of its close association with BMD [ 30 ]. In this study, plasma OC levels were significantly reduced as early as 2 h after the first administered prednisone doses above 10 mg on Day 1.
This decrease was maintained throughout Day 1 and, consistent with the literature [ 31 , 32 ], throughout the treatment period. A similar trend was also observed for P1NP, another biomarker of bone formation.
Furthermore, prednisone increased uNTX, a biomarker of bone loss. Taken together, these data support both decreased bone formation and increased resorption, and demonstrate dose- and time-dependent effects of daily prednisone. Interestingly, biomarkers of bone turnover are thought to be useful in predicting the rate of bone loss in postmenopausal women [ 33 ].
In addition, some of these biomarkers, such as urinary C-telopeptide and free deoxypyridinoline, predict the associated threat of hip fracture independently of BMD [ 34 ], which is thought to be the most important predictor of osteoporotic fracture [ 35 ].
It has also been reported that several of these markers, such as serum OC and the CrossLaps peptide of urinary C-telopeptide, may be used to monitor the efficacy of therapy in patients with osteoporosis [ 36 ]. Furthermore, Garnero et al. Thus, the bone biomarker data in the present study have potential predictive value for subsequent bone-related AEs of GCs.
This study carefully and thoroughly characterized the dose—response of prednisone on two significant safety concerns associated with use of GC: HPA axis suppression and adverse effects on bone metabolism.
The dose- and time-dependent responses to prednisone on the HPA axis and bone biomarkers can be used for comparison with novel glucocorticoid receptor agonists. To demonstrate preliminary evidence of dissociation, however, it is essential to characterize dose—response for putative anti-inflammatory biomarkers of GCs.
In healthy volunteers there is no ongoing inflammation that can be assessed for evidence of dose-dependent suppression. The effects on trafficking of circulating leukocytes may serve as a biomarker for anti-inflammatory effects in healthy volunteers. While not true anti-inflammatory biomarkers, they are likely to be associated with similar GC agonistic effects. This characterization of the dose—response of prednisone on various biomarkers of GC agonism provides important and relevant information on safety and PD responses associated with short-term prednisone dosing over the commonly used clinical dose range, and provides a reference for early clinical development of dissociated agents targeting a differentiated PD profile.
Ann Intensive Care. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol. Morand EF. Effects of glucocorticoids on inflammation and arthritis. Curr Opin Rheumatol. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. The epidemiology of glucocorticoid-associated adverse events.
Article PubMed Google Scholar. Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in rheumatoid arthritis patients: a controlled cross-sectional study. Scand J Rheumatol. Krasselt M, Baerwald C.
The current relevance and use of prednisone in rheumatoid arthritis. Expert Rev Clin Immunol. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.
Osteoporos Int. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis.
Arthritis Rheum. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology Oxford. The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo. Clin Exp Immunol. Endogenous glucocorticoids control neutrophil mobilization from bone marrow to blood and tissues in non-inflammatory conditions. Br J Pharmacol. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.
Phase 2 evaluation of PF, a dissociated agonist of teh glucocorticoid receptor, for the treatment of rheumatoid arthritis in patients with an inadequate response to methotrexate. Google Scholar. Berlin M. Recent advances in the development of novel glucocorticoid receptor modulators. Expert Opin Ther Pat. The effect of Hydrocortisone on the kinetics of normal human lymphocytes. AAPS J. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics.
J Clin Pharmacol. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.
Am J Med. Verhoeven AC, Boers M. Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases.
J Rheumatol. Sambrook P, Lane NE. Corticosteroid osteoporosis. Best Pract Res Clin Rheumatol. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.
Ann Rheum Dis. Glucocorticoid-induced osteoporosis: a review. Clin Rev Bone Miner Metab. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. The course of biochemical parameters of bone turnover during treatment with corticosteroids. Correlation between bone markers and bone mineral density in postmenopausal women with osteoporosis.
Endocr Pract. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res. Changes in calcium and bone metabolism during treatment with low dose prednisone in young, healthy, male volunteers. Clin Rheumatol. Bone density at various sites for prediction of hip fractures. Prevention of early postmenopausal bone loss with cyclical etidronate therapy a double-blind, placebo-controlled study and 1-year follow-up.
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. Download references. Pfizer personnel were involved in protocol development, conducting the study, data analysis and interpretation, and the decision to submit the manuscript for publication. This study was sponsored by Pfizer Inc.
Metrics details. Glucocorticoids GCssuch as prednisone, are the standard of care for several inflammatory and immunologically mediated diseases, but their chronic systemic administration is severely limited by serious adverse effects that are both dose and time dependent.
Short-term treatment 7—14 days with oral prednisone is used for many acute inflammatory and allergic conditions. This study was conducted to characterize the safety and pharmacodynamic PD dose—response of a 7-day course of oral prednisone on biomarkers of GC receptor agonism. In this randomized, single-blind, placebo-controlled, crossover study A37 healthy subjects received placebo or a prednisone dose from 2.
White blood cell counts and plasma samples for measuring cortisol, osteocalcin and procollagen type 1 N-propeptide P1NP were obtained at 2, 4, 8, and 12 h post-dose on Day 1, immediately prior to dosing on Days 1, 2, and 4, and at nominal dosing time on Days 0 and 8.
Urine samples for urinary N-terminal cross-linked telopeptide of type 1 collagen uNTX were collected on Days 0, 1, 2, 4, and 8. Serum samples for adiponectin were obtained prior to dosing on days 0, 1, 4 and 8. Daily doses of prednisone up to 60 mg resulted in dose- and time-dependent decreases in plasma osteocalcin, plasma P1NP, serum cortisol, and absolute blood eosinophil counts.
Absolute blood neutrophil counts increased, while blood lymphocyte counts rebounded to an increased level following an initial rapid decrease after dosing. An increase was observed for uNTX and adiponectin. The incidence of adverse effects with prednisone was not dose related, and nervous system disorders, mainly headache, were the most frequently reported adverse effects.
This characterization provides important and relevant information on safety and PD responses of short-term prednisone dosing over the commonly-used clinical dose range, and also provides a reference for early clinical development of dissociated agents targeting a differentiated PD profile. NCT retrospectively registered: 21 April Peer Review reports. Glucocorticoids GCs are commonly used to manage inflammatory and immunologically-mediated conditions [ 1 — 3 ], and continue to have a prominent place in the clinic despite having a profile of serious adverse effects that are dose- and time-dependent [ 45 ].
Due to these known serious adverse effects, a GC such as prednisone is used at the lowest effective dose 5—7. One of the most prevalent adverse effects is that on bone remodeling, specifically, an uncoupling of bone formation and resorption in favor of bone loss via direct effects on osteoblasts [ 8 ].
Indeed, the most common form of iatrogenic osteoporosis is GC induced [ 9 ]. Many other adverse effects, such as electrolyte imbalance, weight gain, and metabolic disturbances, result from GC-induced effects on other tissues including the hypothalamic-pituitary-adrenal HPA axis [ 1011 ]. Similarly, due to a plethora of effects on leukocytes and vascular endothelial cells, such as altered cell distribution patterns, immobilization, and apoptosis, GC therapy can result in dramatic changes in circulating white blood cell profiles that may contribute to an increased risk of GC-associated infection [ 12 — 14 ].
Recent drug discovery and development efforts have focused on approaches to reduce adverse effects, while maintaining efficacy of GC therapy. These approaches include development of a modified-release prednisone formulation and discovery of selective GC receptor ligands that putatively dissociate anti-inflammatory effects mediated by genomic transrepression from adverse effects mediated by genomic transactivation [ 715 — 18 ].
Despite the present understanding of the known adverse effects of GC therapy, and recent drug development efforts to potentially dissociate efficacy and safety of GCs, the dose—response and time course of the effect of current GCs on various biomarkers of GC receptor agonism anti-inflammatory and adverse effects have not been systematically characterized. The characterization of the safety and pharmacodynamics PD of multiple doses of a standard GC such as prednisone, over the commonly used clinical dose range 2.
The present study was conducted to further characterize the safety and dose—response of 7-day prednisone administration using biomarkers of GC receptor agonism in a healthy adult population.
Subjects with evidence or history of clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease including drug allergies, but excluding untreated, asymptomatic seasonal allergies at time of dosing or any condition possibly affecting drug absorption were excluded from the study.
This randomized, single-blind, placebo-controlled, crossover study A was designed to characterize the dose—response of prednisone on biomarkers of GC receptor agonism. Within 28 days of screening, all eligible subjects were randomly assigned to one of seven treatment sequences, each with three 7-day treatment periods separated by a day washout period Table 1. The treatments in each sequence included either three of the six prednisone doses evaluated in the study 2.
In the first treatment period only, all subjects had baseline assessments on Day 0, the day prior to dosing. Serum samples for morning cortisol were obtained immediately prior to dosing or nominal dosing time on Day 0 baseline, day prior to first dosing and on Days 1 first day of dosing2, 4, and 8, in each of the three 7-day treatment periods.
Serum samples for cortisol were obtained at 2, 4, 8, and 12 h following the first sample on Day 0 Period 1 only and following the first prednisone dose on Day 1. A radioimmunoassay Roche Diagnostics, Indianapolis, IN was used initially for measurement of cortisol in serum, but the results indicated the possibility of assay interference from prednisone and its metabolite prednisolone.
Stability of cortisol was confirmed in plasma for a time period greater than the duration of storage with up to three freeze-thaw cycles. Serum was also obtained for assaying cortisol levels on Day 8 before and 30 min after low-dose adrenocorticotropic hormone ACTH stimulation. Subjects with an abnormal low-dose ACTH stimulation response on Day 8 were administered the test again after 2 weeks.
A radioimmunoassay was used for measurement of serum cortisol from the low-dose ACTH stimulation test. Assay interference from prednisone and prednisolone was considered unlikely, since complete washout of both moieties was expected at the time these samples were obtained.
Complete blood count with differential data for neutrophils, eosinophils, and lymphocytes are shown was obtained at 2, 4, 8, and 12 h post-dose on Day 1, immediately prior to dosing on Days 1, 2, and 4, and at nominal dosing time on Days 0 and 8. Plasma samples for OC, a biomarker of bone formation, were collected serially on Day 0 at nominal dosing time and 2, 4, 8, and 12 h thereafter and serially post-dose on Day 1 2, 4, 8, and 12 himmediately prior to dosing on Days 1, 2, and 4, and at nominal dosing time on Day 8; plasma samples for procollagen type 1 N-propeptide P1NPalso a bone formation marker, were collected 12 h post-dose on Day 1, immediately prior to dosing on Days 2 and 4, and on Days 0 and 8.
Urine samples for urinary N-terminal cross-linked telopeptide of type 1 collagen uNTXa biomarker of bone resorption, were collected from the second pre-noon voiding of the bladder on Days 0, 1, 2, 4, and 8.
OC and uNTX were assayed using an enzyme-linked immunosorbent assay method. P1NP was assayed by a validated radioimmunoassay. A kinetic modification of the Jaffe reaction was used for the quantitative measurement of urinary creatinine uCr.
Pacific Biometrics, Inc. Serum samples for fasting glucose and insulin were obtained immediately prior to dosing on Days 0, 1, 2, 4, 6, and 7. For the oral glucose tolerance test OGTTthe subjects were to ingest 75 g of a glucose solution within 5 min of receiving study medication on Day 6; this solution was to be ingested within 10 min, and blood samples for glucose were then collected at 0. Serum samples for triglycerides were obtained immediately prior to dosing on Days 0, 1 and 4, and on Day 8 and, for adiponectin, immediately prior to dosing on Days 0, 1 and 4, and on Day 8.
Adverse events AEs were monitored throughout, and vital signs sitting blood pressure and pulse rate were performed at screening and prior to dosing on Days 0, 1, 4, and 8; laboratory safety tests hematology, blood chemistry, urinalysis, and hormone and chronic infection testswere performed at screening and on Day 0; a post-void weight was taken at screening and on Days 1 and 8 of each treatment period.
The change from baseline in primary biomarker endpoints biomarkers of AEs and biomarkers of anti-inflammatory activity for each prednisone dose was compared with the change from baseline for placebo, using a repeated-measures crossover analysis of covariance model containing effects for sequence, period, time, dose, time by dose interaction, and subject within sequence as random effectas well as baseline as a covariate.
Overall, 37 subjects were screened; all were assigned to study treatment. Five subjects were assigned to each of the seven treatment sequences A-G and received either three active doses of prednisone 2. Ultimately, each of the treatments was received by 15 or 16 subjects. The proportion of subjects completing the study was Two subjects in treatment sequence E prednisone 20 mg, 40 mg, and placebo in Periods 1, 2, and 3, respectively and one subject in treatment sequence G prednisone 60 mg, placebo, and prednisone 5 mg in periods 1, 2, and 3, respectively discontinued from the study.
The subject in treatment sequence G discontinued during Period 2 while receiving placebo due to AEs related to the study treatment. The other two subjects discontinued from the study for reasons not related to study treatment; both subjects withdrew consent.
One subject in treatment sequence E was also discontinued during Period 2 while receiving prednisone 40 mg; both subjects that discontinued during Period 2 were replaced following approval by the study statistician. The other subject in treatment sequence E was in treatment period 1 at discontinuation, and was not replaced. Demographic characteristics were similar among the treatment groups.
Subjects were aged between 18 and 50 years, and the majority were white and male Table 2. Plasma cortisol concentrations decreased rapidly following the first dose of prednisone, and then recovered in a dose-dependent manner Fig.
Mean serum cortisol concentrations up to 24 h following the first daily dose of prednisone. Pretreatment cortisol concentrations over 24 h were measured in all subjects the day prior to the first day of dosing in Period 1.
Two subjects required a third test and one subject required a fourth test before their responses returned to normal.
The two subjects who did not achieve a normal response within 2 weeks received prednisone doses of either 40 mg or 60 mg in the last treatment period. Daily doses of prednisone up to 60 mg resulted in dose- and time-dependent effects on white blood cell counts. Eosinophil counts relative to placebo demonstrated acute dose-dependent reductions on Day 1. A significant reduction versus placebo was observed as early as 2 h post-dose with prednisone 60 mg Fig.
At 4 h reductions were significant at all doses, and from 4—12 h counts relative to placebo were relatively stable Fig. Reductions in eosinophil counts relative to placebo were seen at most doses on Day 8 Fig.
Mean change from baseline difference from placebo in white blood cell counts. Eosinophil, neutrophil, and lymphocyte counts for Day 1 by hour ace and for Days 1 through 8 bdf for each daily prednisone dose. Differences in neutrophil counts relative to placebo were variable over the next 7 days: significant increases were observed with higher doses on Days 2 and 8, whereas decreases, which were significant with the lower doses, were seen on Day 4 Fig.
As was observed with neutrophil counts, lymphocyte counts demonstrated acute dose-dependent reductions versus placebo on Day 1, with significant reductions observed with all doses as early as 2 h post-dose Fig. Reductions in lymphocyte counts relative to placebo were greatest with most doses at 4 h post-dose, and were similar to placebo with the lower doses at 12 h post-dose Fig.
Daily doses of prednisone up to 60 mg resulted in dose- and time-dependent effects on biomarkers of bone metabolism.
OC and P1NP are biomarkers of bone formation. On Day 1, plasma OC significantly decreased relative to placebo as early as 2 h post-dose, and continued to decrease in a dose-dependent manner until 12 h post-dose Fig.
P1NP levels increased slightly relative to placebo on Day 2, and then decreased in a dose- and time-dependent manner until Day 8 Fig. Mean change from baseline difference from placebo in biomarkers of bone metabolism. Urinary NTX is a biomarker of bone loss. The results for fasting glucose and insulin on Days 1 and 8 are shown in Table 4. Increases from baseline in both glucose and insulin concentrations at 0. After 6 days of prednisone treatment, the changes from baseline in both glucose and insulin concentrations relative to placebo were not significant at most time points data not shown.
The effect of prednisone relative to placebo on serum triglyceride levels was variable. On Day 1, prednisone 20 mg and 40 mg significantly raised triglyceride levels. On Day 8, prednisone raised triglyceride levels, but the relationship to dose was inconsistent, and the impact generally was not significant Table 4. Dose- and time-dependent effects of prednisone on adiponectin were also observed relative to placebo.
On Day 8, adiponectin was significantly increased with higher prednisone doses Table 4. However, no clear pattern for the treatment arms appeared in either assessment.
There were no serious adverse events SAEs or deaths reported. There were no clinically significant changes in vital signs or body weight at any time point. The incidence of AEs with prednisone was not dose related. Three subjects reported severe AEs; all were headaches experienced while on prednisone 2. This study was designed to characterize the dose—response and time course of prednisone effects on biomarkers of GC receptor agonism in a healthy adult population over 7 days.
Daily doses of prednisone up to 60 mg were generally well-tolerated and resulted in dose- and time-dependent effects on a number of biomarkers. As would be expected, a decrease relative to placebo was noted in biomarkers of bone formation OC and P1NPwhereas there was an increase in a biomarker of bone turnover uNTX.
It has been demonstrated that prednisolone enema is efficacious in downregulating the factors that favor neutrophil recruitment and their local. It can be concluded that even small doses of prednisone, administered over a prolonged period of time, can induce extreme and persistent leukocytosis. This. Clarification of the effect of inhaled CS administration on WBC and ANC is important for the proper interpretation of the blood cell counts of. Glucocorticoids (e.g., dexamethasone, methylprednisolone, prednisone) are known to increase the white blood cell (WBC) count upon their initiation. The increase. Anti-inflammatory effects of prednisone . Peer Review reports. Pacini G Mari A. A radioimmunoassay was used for measurement of serum cortisol from the low-dose ACTH stimulation test. Krasselt M, Baerwald C. Allergen 0. OC and P1NP are biomarkers of bone formation. Your current browser may not support copying via this button.The white blood cell WBC count is a routine laboratory test that reflects the number of leukocytes or WBC distributed in the blood. It is evident that the neutrophils make up the greatest percentage of leukocytes and thus can have the greatest impact on changes in the WBC count. Neutrophils are also called polymorphonuclear leukocytes PMN because of the number of stages they go through during their life cycle. They are initially released from the bone marrow as immature neutrophils that are characterized as having a nonsegmented, band like appearing nucleus.
As such, these immature neutrophils are called "bands". An increase in the number of these immature neutrophils in circulation can be indicative of a bacterial infection for which they are being generated to fight. This is known as the "left shift" seen in a WBC differential. These and other neutrophils can be found in several compartments in the body, but the two compartments that relate most to this newsletter are the marginal compartment those neutrophils attached to the endothelium of the blood vessel and the circulating compartment those circulating in the blood vessels along with other cells.
Understanding this information is critical for the proper assessment of an elevated WBC count, especially when glucocorticoids e. While glucocorticoids are used to inhibit inflammation and the immune response in certain clinical situations, their initiation may also cause an increase in the WBC count.
Since increases in PMNs can be associated with bacterial infections, the use of the WBC differential can be helpful at determining whether or not the increase in WBC count was from a bacterial infection or the initiation of glucocorticoids. The initiation of glucocorticoids does not usually cause the same degree of a "left shift" that is normally associated with presence of a bacterial infection. Determining the cause of the WBC increase is especially important, and often more difficult, in the immunocompromised patient.
What are main causes of steroid induced increases in the WBC count? The answer is a multifactorial culmination of the following biological effects of the glucocorticoids. It is common for patients to reveal a leukocytosis increased WBC count within 24 hours of initiation of a glucocorticoid.
It is important for clinicians to be aware of this expected side effect and to understand the rationale for such an increase as well as appropriate interpretation of the labs given the patient's clinical condition. Keeping all of these things in mind will help clinicians avoid unnecessary medical work-up for other conditions and avoid patient exposure to additional drug therapy that is not warranted, such as intravenous antibiotics. About Us Disclaimer Contact Us.
Toggle navigation. Please enter text to search. Search by Outlines. Set Search Limits. Summary : Glucocorticoids e. As such, it is important for clinicians to consider these effects in order to properly assess the increase in WBC counts so that a new or underlying bacterial infection is not missed. Patients with glucocorticoid induced leukocytosis generally will not present with the typical "left shift" in the WBC differential seen during an acute bacterial infection, nor should they develop a fever or experience a worsening of clinical symptoms assuming that the initial treatments are appropriate for the condition being treated.
Editor-in-Chief: Anthony J. Explanation The white blood cell WBC count is a routine laboratory test that reflects the number of leukocytes or WBC distributed in the blood. The greatest effect is demargination of the neutrophils from the endovascular lining. As a result, when a lab is drawn via venipuncture from a patient to determine the WBC count, there will now be a greater number of circulating PMNs.
However, it is important to note that the total number of PMNs has not changed, just the percentage of PMNs residing in each compartment. Junqueira LC, Carneiro J. Blood cells. In: Basic Histology. Junqueira LC, Caneiro J eds. New York, NY. Abramson N, Melton B. Leukocytosis: basic of clinical assessment. Am Fam Physician ; Prednisone-induced leukocytosis.
Influenced of dosage, method and duration of administration on the degree of leukocytosis. Am J Med ; Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation ; Regulation of L-selectin and CD18 on bovine neutrophils by glucocorticoids: effects of cortisol and dexamethasone.
J Leukoc Biol ; L-selectin expression on polymorphonuclear leukocytes and monocytes in premature infants: reduced expression after dexamethasone treatment for bronchopulmonary dysplasia. J Pediatr ; Mechanisms of glucocorticoid-induced down-regulation of neutrophil L-selectin in cattle: evidence for effects at the gene-expression level and primarily on blood neutrophils. Glucocorticoids inhibit apoptosis of human neutrophils.
Blood ; Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol ; Leukokinetic studies. A non-steady-state kinetic evaluation of the mechanism of cortisone-induced granulocytosis. J Clin Invest ;
